Plain-English translation of NCT06549790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it can help people with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatments. The study will first test different doses of the medication to find the safest and most effective dose. Then, researchers will expand the trial to study the medication more carefully in two groups of patients: those with a specific genetic change (TP53 mutation) and those without it.
People with relapsed or refractory AML have very limited options—their cancer has either returned after initial treatment or never responded to it in the first place. Current standard treatments often don't work well enough for these patients, and many have already tried multiple therapies. This trial exists to see whether this new medication could offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once daily for 28 consecutive days, then repeat this cycle as long as you and your doctor decide it is helping and tolerable. The trial has two phases: first, researchers test increasing doses to find the right amount, then they expand the study with specific groups of patients. You'll need to visit the clinic regularly for blood tests, exams, and to pick up your medication. The study will monitor how well the medication works and what side effects you experience.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States